Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease.
BACKGROUND
Glucagon-like peptide-1 (GLP-1) is an incretin hormone that has a wide range of effects on glucose metabolism and cardiovascular function (e.g., improving insulin sensitivity, reduction in appetite, modulation of heart rate, blood pressure and myocardial contractility). Metabolic syndrome (MetS) is associated with an increased risk of developing atherosclerotic cardiovascular diseases. Novel glycemic control drugs, the dipeptidyl-peptidase-4 (DPP-4) inhibitors, work by inhibiting the inactivation of incretin hormones, GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). In spite of good effects of these drugs in diabetic patients, circulating levels of incretins and their role in MetS are largely unknown.


METHODS
To examine relationships between incretin hormones and MetS risk factors, we measured circulating levels of incretins in obese high-risk patients for cardiovascular disease. Fasting serum GLP-1 and GIP levels were measured by ELISA. We performed a cross-sectional analysis of metabolic variables in the fasting state in two subject groups: with MetS (n = 60) and pre-MetS (n = 37).


RESULTS
Fasting levels of Serum GLP -1 in the peripheral circulation were significantly increased correlated with the accumulation of MetS risk factors components (r = 0. 470, P < 0.001). There was a significant interaction between circulating GLP-1 and GIP, serum high-density lipoprotein cholesterol, triglyceride, and serum uric acid concentrations but not waist circumference, fasting glucose, HbA1c, or presence of diabetes.


CONCLUSIONS
Circulating levels of GLP-1 in relation to the accumulation in MetS factors suggested that MetS patients with elevated levels of GLP-1 are high-risk patients for cardiovascular disease, independent with the presence of diabetes.
Yamaoka-Tojo
Minako
M
Department of Rehabilitation, Kitasato University School of Allied Health Sciences, 1-15-1 Kitasato, Minami-ku, Sagamihara, 252-0373, Japan. myamaoka@med.kitasato-u.ac.jp
Tojo
Taiki
T
Takahira
Naonobu
N
Matsunaga
Atsuhiko
A
Aoyama
Naoyoshi
N
Masuda
Takashi
T
Izumi
Tohru
T
D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000032:analysis; D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology* / Q000503:physiopathology; D016009:Chi-Square Distribution; D008076:Cholesterol, HDL / Q000097:blood; D003430:Cross-Sectional Studies; D003920:Diabetes Mellitus / Q000097:blood / Q000503:physiopathology; D004797:Enzyme-Linked Immunosorbent Assay; D005215:Fasting / Q000097:blood; D005260:Female; D005749:Gastric Inhibitory Polypeptide / Q000097:blood; D052216:Glucagon-Like Peptide 1 / Q000097:blood*; D006442:Glycated Hemoglobin; D006801:Humans; D007333:Insulin Resistance; D007564:Japan; D016015:Logistic Models; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood* / Q000150:complications / Q000503:physiopathology; D008875:Middle Aged; D056128:Obesity, Abdominal / Q000097:blood* / Q000150:complications / Q000503:physiopathology; D016017:Odds Ratio; D018570:Risk Assessment; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood; D015854:Up-Regulation; D014527:Uric Acid / Q000097:blood; D055105:Waist Circumference
D015415:Biomarkers; D001786:Blood Glucose; D008076:Cholesterol, HDL; D005749:Gastric Inhibitory Polypeptide; D052216:Glucagon-Like Peptide 1; D006442:Glycated Hemoglobin; D014280:Triglycerides; D014527:Uric Acid; C517652:hemoglobin A1c protein, human
J Clin Endocrinol Metab. 2001 Aug;86(8):3717-23
11502801
Curr Opin Lipidol. 1996 Jun;7(3):167-71
8818515
J Pharmacol Exp Ther. 2006 Jun;317(3):1106-13
16489128
Am J Med. 2008 May;121(5):426-32
18456039
Arterioscler Thromb Vasc Biol. 2008 Apr;28(4):629-36
18174459
Gastroenterology. 2007 May;132(6):2131-57
17498508
Circulation. 2005 Oct 25;112(17):2735-52
16157765
Am J Med. 2009 Jun;122(6 Suppl):S37-50
19464427
Circulation. 2007 Mar 20;115(11):1345-53
17339551
Ann Surg. 2006 Jan;243(1):108-14
16371744
Drugs. 2008;68(15):2131-62
18840004
Neuroimage. 2007 Apr 1;35(2):511-7
17317222
J Clin Endocrinol Metab. 2009 Jul;94(7):2558-64
19366852
Rev Diabet Stud. 2006 Winter;3(4):208-16
17487346
Acta Psychiatr Scand. 2009 Jan;119(1):4-14
19133915
Endocr Rev. 2008 Dec;29(7):777-822
18971485
Am J Cardiol. 2007 Sep 1;100(5):824-9
17719327
Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14843-7
10611300
Lancet. 2009 Nov 7;374(9701):1570-1
19853907
J Clin Invest. 2007 Jan;117(1):143-52
17187081
Br J Pharmacol. 2009 Aug;157(8):1340-51
19681866
J Clin Endocrinol Metab. 2007 Feb;92(2):399-404
17284640
JAMA. 2008 Mar 12;299(10):1185-7
18334695
Cardiovasc Drugs Ther. 2007 Aug;21(4):253-6
17541736
Br J Surg. 2006 Feb;93(2):210-5
16392104
Mol Endocrinol. 2006 Jul;20(7):1644-51
16469773
Lancet. 1987 Dec 5;2(8571):1300-4
2890903
J Clin Invest. 1995 Jan;95(1):417-21
7814643
Nature. 1996 Jan 4;379(6560):69-72
8538742
Cardiovasc Diabetol. 2009 Jul 20;8:38
19619327
Chin Med J (Engl). 2008 Nov 5;121(21):2134-8
19080172
Am J Hypertens. 2007 Jan;20(1):83-9
17198917
J Clin Endocrinol Metab. 2007 Dec;92(12):4678-85
17895322
Physiol Rev. 2007 Oct;87(4):1409-39
17928588
J Clin Endocrinol Metab. 1986 Aug;63(2):492-8
3522621
N Engl J Med. 1996 Feb 8;334(6):374-81
8538710
Circulation. 2004 Mar 2;109(8):962-5
14981009
Diabetes. 2001 Mar;50(3):609-13
11246881
JAMA. 2002 Dec 4;288(21):2709-16
12460094
Circulation. 2008 May 6;117(18):2340-50
18427132
Obes Surg. 2005 Apr;15(4):474-81
15946424
Nat Med. 2002 Jul;8(7):738-42
12068290
Diabetes. 2009 Apr;58(4):975-83
19151200
J Atheroscler Thromb. 2006 Aug;13(4):202-8
16908953
Diabetes. 2005 Jan;54(1):146-51
15616022
Diabetologia. 1985 Jul;28(7):412-9
3899825
J Clin Invest. 1996 Jan 1;97(1):92-103
8550855